Cartesian Therapeutics, Inc. (RNAC) Net margin 2016–2025
Cartesian Therapeutics, Inc. (RNAC) net profit margin by fiscal year — reported net income divided by reported revenue.
-32575.5%FY2025 · since FY2016: -448.0% → -32575.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -32575.5% | -32373.2 pp |
| FY2024 | -202.3% | +642.6 pp |
| FY2023 | -844.9% | -876.8 pp |
| FY2022 | 31.9% | +62.1 pp |
| FY2021 | -30.2% | +384.8 pp |
| FY2020 | -415.0% | +414.0 pp |
| FY2019 | -829.0% | +6406.5 pp |
| FY2018 | -7235.4% | +24320.6 pp |
| FY2017 | -31556.0% | -31108.1 pp |
| FY2016 | -448.0% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More RNAC financial trends
RNAC RevenueRNAC Net incomeRNAC Gross profitRNAC Gross marginRNAC Operating incomeRNAC Operating marginRNAC Operating cash flowRNAC Free cash flowRNAC Capital expendituresRNAC Return on equityRNAC Stock buybacksRNAC Dividends paidRNAC Total assetsRNAC Total liabilitiesRNAC Shareholders’ equityRNAC overview →